Search clinical trials for: Prior treatment regimen included trastuzumab

Total 69097 results

Daiichi Sankyo
AstraZeneca

Completed

DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

Adenocarcinoma Gastric Stage IV With Metastases | Adenocarcinoma - GEJ

United States, Spain, Belgium, Italy, United Kingdom
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (TH3RESA)

Breast Cancer

Belgium, Israel, Spain, Sweden, United States, Switzerland, Russian Federation, Czech Republic, France, Canada, Germany, Korea, Republic of, Australia, Hungary, Thailand, United Kingdom, Italy, Brazil, Slovakia, Poland, India, Norway
AstraZeneca

Not yet recruiting

A PROSPECTIVE, MULTI-CENTER, PHASE 4 STUDY TO ASSESS THE SAFETY OF TRASTUZUMAB DERUXTECAN, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE IN INDIAN PATIENTS WITH UNRESECTABLE OR METASTATIC HER2-POSITIVE BREAST CANCER WHO HAVE RECEIVED A PRIOR ANTI-HER2-BASED REGIMEN (STRIDE)

BREAST CANCER
Sun Jing

Not yet recruiting

Nocardia Rubra Cell Wall Skeleton in Combination With Prior Second- or Third-line Regimens for the Treatment of Potentially Hazardous Colorectal Cancer SD Status

Colorectal Neoplasms | Colorectal Cancer
Beijing 302 Hospital

Recruiting

Efficacy of T-Dxd in the Treatment of HER2-positive BCBM After Prior Pyrotinib

Breast Cancer

China
Xuekui Liu

Not yet recruiting

A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. (B2023-153)

Oral Squamous Cell Carcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company

Recruiting

A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)

HER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction Adenocarcinoma

Austria, Belgium, Germany, Italy
Henan Cancer Hospital

Recruiting

Comparing the Efficacy of Nab-PH+Pyrrolitinib and TCbHP in the Neoadjuvant Treatment of HER2 Positive BC

Breast Cancer | HER2-positive Breast Cancer

China
Brown University
AstraZeneca

Recruiting

Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction

Esophageal Cancer | Esophageal Adenocarcinoma | HER-2 Protein Overexpression | Gastroesophageal-junction Cancer

United States
iOMEDICO AG
Seagen Inc.

Recruiting

Tucatinib in Patients With Locally Advanced or Metastatic HER2-positive Breast Cancer Who Received at Least Two Prior Anti-HER2 Treatment Regimens. (TRACE)

HER2-positive Breast Cancer

Germany, Austria
AIPING ZHOU

Not yet recruiting

SOX Combined With Sintilimab and Trastuzumab Versus SOX Regimen in the Perioperative Treatment of HER2-positive Locally Advanced Gastric Adenocarcinoma

Immunotherapy | Sintilimab | Locally Advanced Solid Tumor | Oxaliplatin | HER2-positive | Gastric or Gastroesophageal Junction Adenocarcinoma | S-1

China
Fundación Pública Andaluza para la gestión de la...
Spanish Clinical Research Network - SCReN; CIBER (Infectious diseases)

Recruiting

Efficacy and Safety of 7 Versus 14 Days of Antibiotic Treatment for Pseudomonas Aeruginosa Bacteraemia (SHORTEN2)

Bloodstream Infection

Spain
Affiliated Hospital to Academy of Military Medical...
Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Peking...

Recruiting

Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Age Range ≥16 Years, Gender Unlimited | Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma | Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed | At Least One Positive Lesion According to the 2014... and other conditions

China
Fudan University

Recruiting

Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment

Breast Cancer

China
Fujian Medical University

Recruiting

Low-dose AZA Combined With Short Term CAG Derived Regimen as a Bridging Treatment in Patients With Advanced MDS Prior to Allo-HSCT

MDS-EB

China
Massachusetts General Hospital
Stand Up To Cancer

Recruiting

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

Metastatic Colon Cancer | Stage III Colon Cancer

United States
Jounce Therapeutics, Inc.

Terminated

Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen (SELECT)

NSCLC

Latvia, Bosnia and Herzegovina, Russian Federation, Romania, Turkey, Belarus, Bulgaria, Croatia, Hungary, Serbia, Slovakia, Ukraine, Georgia, Moldova, Republic of
AstraZeneca
Daiichi Sankyo Co., Ltd.

Completed

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens (DG-06)

Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

China
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer

Breast Cancer

Belgium, Netherlands, France, Egypt, South Africa, United Kingdom, Denmark, Serbia, Poland
Henan Cancer Hospital

Withdrawn

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer

China
Memorial Sloan Kettering Cancer Center
Hoffmann-La Roche; Genentech, Inc.; Hartford HealthCare

Active, not recruiting

Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab, or Pertuzumab Based Therapy

Metastatic HER2-Positive Breast Cancer

United States
Fudan University
Henan Cancer Hospital

Completed

Rechallenge of Prior Regimen in Third or Later-line Chemotherapy in Metastatic Colorectal Cancer

Metastatic Colorectal Cancer | Chemotherapy Effect

China
Tanta University

Completed

Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection

Hepatitis C

Egypt
Bristol-Myers Squibb
PPD

Completed

An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLC (Checkmate 171)

Non-Small Cell Lung Cancer

Poland, Spain, Austria, Denmark, Finland, Greece, Hungary, Ireland, Portugal, Romania, Russian Federation, Sweden, United Kingdom
Bristol-Myers Squibb

Completed

A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen (CheckMate153)

Non Small Cell Lung Cancer (NSCLC)

United States, Canada
Hoffmann-La Roche

Completed

Safety and Efficacy of Trastuzumab as Part of Breast Cancer Treatment Regimen

Breast Cancer

India
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

Breast Cancer

Italy, Belgium, Canada, United Kingdom, Argentina, Australia, Austria, Brazil, Bulgaria, China, Croatia, Denmark, Dominican Republic, Ecuador, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, Indonesia, Irelan... and more
National Institute of Allergy and Infectious Diseases...
Eunice Kennedy Shriver National Institute of Child Health and Human Development...

Completed

A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy

HIV Infections

United States
Puma Biotechnology, Inc.

Completed

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

HER2+ Metastatic Breast Cancer (MBC)

United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Indian Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane

HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer

India
Bristol-Myers Squibb

No longer available

Expanded Access Program With Nivolumab Therapy for Treatment of Advanced/Metastatic SqNSCLC or Non-SqNSCLC After One Prior Systemic Regimen (CheckMate 169)

Non-squamous Non-Small Cell Lung Cancer | Squamous Non-Small Cell Lung Cancer

Brazil, Canada
Boehringer Ingelheim

Completed

LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment

Breast Neoplasms

Korea, Republic of, Spain, Canada, Germany, Singapore, China, United Kingdom, Taiwan, Israel, United States, Australia, Slovenia, Italy, Brazil, India, Czechia, Netherlands, Ireland, Poland, Belarus, Belgium, Portugal, Russian Federation and more
Kern Pharma, S.L.
Analysis and Research Network, S.L

Unknown

Clinical Trial to Investigate the Effectiveness of a Dietary Supplement in Increasing Libido and Sexual Function in Postmenopausal Women.

Female Sexual Arousal Disorder

Spain
GlaxoSmithKline

Completed

Breast Cancer With Over-expression of erbB2-BRAINSTORM

Cancer

Thailand, Singapore, Philippines
Merck Sharp & Dohme LLC

Terminated

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Neoplasms
Eli Lilly and Company

Completed

Study Using IMC-A12 (Cixutumumab) With or Without Cetuximab in Participants With Metastatic Colorectal Cancer Who Have Failed a Treatment Regimen That Consisted of a Prior Anti-EGFR Therapy

Colorectal Cancer

United States
ViiV Healthcare

Completed

Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Italy
Merck Sharp & Dohme LLC

Withdrawn

Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)

Chronic Genotype 1 Hepatitis C Virus Infection
Bristol-Myers Squibb

Completed

Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy (STRUCTURE)

Hepatitis C

France, Germany, Italy, Japan, Korea, Republic of, Russian Federation, Taiwan, United Kingdom, United States, Spain, Israel, Argentina, Poland
Pfizer

Completed

A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen

Non-small Cell Lung Cancer

United States, Taiwan, Korea, Republic of, Australia, Brazil, Spain, United Kingdom, Singapore, Canada, Hong Kong, Poland, Puerto Rico
Vertex Pharmaceuticals Incorporated

Terminated

Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype (CONCISE)

Hepatitis C, Chronic

United States, Austria, Canada, Germany, Israel, Poland
ArQule, Inc. (a wholly owned subsidiary of Merck...

Withdrawn

A Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen

Gastric Cancer
Alfacell

Unknown

ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen

Malignant Mesothelioma

United States, Poland, Italy, Germany
Sanofi

Completed

Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

Breast Cancer

United States
Agennix

Terminated

Expanded Access Study of Satraplatin Plus Prednisone in Patients With Hormone Refractory Prostate Cancer (HRPC) (SPERA)

Prostate Cancer

United States
Agennix

Completed

Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen

Prostate Cancer | Hormone Refractory Prostate Cancer

United States, United Kingdom, France, Italy, Israel, Germany, Hungary, Argentina, Russian Federation, Belgium, Croatia, Netherlands, Peru, Poland, Spain
Sanofi

Completed

Pilot Study of the Safety & Efficacy of Two Docetaxel-Based Regimens Plus Bevacizumab for the Adjuvant Treatment of Subjects With Node Positive or High Risk Node Negative Breast Cancer

Breast Neoplasms

United States
BioCryst Pharmaceuticals

Terminated

Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens

Lymphoma | Leukemia

United States
Ann & Robert H Lurie Children's Hospital of Chicago

Unknown

Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies

Lymphoma, Malignant | Leukemia, Myelogenous, Chronic | Leukemia, Lymphoblastic, Acute | Leukemia, Myelogenous, Acute | Myeloproliferative-Myelodysplastic Diseases

United States
Zhou Chengzhi
Guangdong Provincial Hospital of Traditional Chinese Medicine; Sun Yat-sen... and other collaborators

Not yet recruiting

Liposomal Irinotecan Combination Regimen for First-line Treatment of Small Cell Lung Cancer

Small Cell Lung Cancer

3

Subscribe